 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Stockwinners Market Radar for September 30, 2018 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
| TSLA... | Hot Stocks19:26 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. The Securities and Exchange Commission announced that Elon Musk, CEO and Chairman of Tesla (TSLA), has agreed to settle the securities fraud charge brought by the SEC against him last week. The SEC also charged Tesla with failing to have required disclosure controls and procedures relating to Musk's tweets, a charge that Tesla has agreed to settle. According to the settlements, Musk will step down as Tesla's Chairman and be replaced by an independent Chairman, with Musk ineligible to be re-elected Chairman for three years. Meanwhile, Tesla will appoint a total of two new independent directors to its board and will establish a new committee of independent directors and put in place additional controls and procedures to oversee Musk's communications. Further, Musk and Tesla will each pay a separate $20M penalty. 2. A European Union privacy watchdog could fine Facebook (FB) as much as $1.63B for a data breach in which hackers compromised the accounts of more than 50M users, if regulators find the company violated the bloc's strict new privacy law, according to The Wall Street Journal. 3. Potential electoral results could favor the outlook for policies beneficial to a wide range of hospital, pharmaceutical, and other health-care-related companies, Lauren Rublin wrote in this week's edition of Barron's. Policy experts favor Centene (CNC), WellCare Health (WCG), Molina Healthcare (MOH), HCA Healthcare (HCA), Tenet (THC), Encompass Health (EHC), Becton Dickinson (BDX), Cerner (CERN), Dentsply Sirona (XRAY) and Teladoc Health (TDOC) as beneficiaries of Medicaid expansion under the Affordable Care Act, the reported noted, adding that is especially likely if Democrats win more state elections. 4. Comcast (CMCSA) subsidiary Universal's "Night School" debuted to $28M from 3,010 theaters, taking the number one spot of the domestic box office. Overseas, Kevin Hart and Tiffany Haddish's raucous comedy launched to $5.5M from its first 19 markets for $33.5M globally. The movie earned an A- CinemaScore and sports 30% Rotten Tomatoes score. 5. Hasbro (HAS), Royal Dutch Shell (RDS.B, RDS.A), Sanofi (SNY), and IBM (IBM) saw positive mentions in Barron's, while Trupanion's (TRUP) and Tesla were mentioned cautiously.
|
| T... | Hot Stocks17:21 EDT Box Office Battle: 'Night School' opens to $28M in the U.S. - Comcast (CMCSA) subsidiary Universal's "Night School" debuted to $28M from 3,010 theaters. Overseas, Kevin Hart and Tiffany Haddish's raucous comedy launched to $5.5M from its first 19 markets for $33.5M globally. The movie earned an A- CinemaScore and sports 30% Rotten Tomatoes score. BOX OFFICE RUNNERS-UP: AT&T (T) subsidiary Warner Bros' "Smallfoot" opened in second place with $23M from 4,131 theaters. Behind it was Universal's "The House With a Clock in its Walls," finishing Sunday with a domestic total of $44.8M and $65.8M worldwide. Lionsgate's (LGF.A, LGF.B) "A Simple Favor" placed number four, earning $6.6.M domestically. Rounding out the top five, Warner Bros' "The Nun" grossed $5.4M for a domestic cume of $109M. Other publicly traded companies in filmmaking include 21st Century Fox's (FOX, FOXA), Sony (SNE), Viacom (VIAB) and Disney's (DIS).
|
| LMT | Hot Stocks12:14 EDT Lockheed Martin appoints Joseph Rank to lead Saudi operations - Lockheed Martin announced Brigadier General Joseph Rank as the Chief Executive for Lockheed Martin Saudi Arabia. Rank will lead the company's growing business in the Kingdom with responsibilities for building and cultivating key partner relationships and supporting the Kingdom's strategic business pursuits. Rank takes over the position from Alan Chinoda who will be returning to Lockheed Martin based in the United States.
|
| AKTX | Hot Stocks12:13 EDT Akari announces new data in post-transplant thrombotic microangiopathies - Akari Therapeutics announced new clinical data in post-transplant thrombotic microangiopathies. HSCT-TMA is a complication in up to 30% of patients following bone marrow transplantation. In severe cases, pediatric TMA carries a mortality of more than 80%1. Currently, HSCT-TMA has no approved treatment. In both of the pediatric patients treated with Coversin, there was rapid reduction of the markers of complement activation and normalization of markers that are elevated in TMA: platelet count, red blood cell fragments, thrombocytopaenia, elevated LDH, and hypertension. The child treated at GOSH made a complete recovery and Coversin was discontinued after seven weeks. In the second patient, despite resolution of the TMA markers, the patient subsequently died of lung damage which was considered unrelated to treatment with Coversin. Akari intends to move from supplying Coversin for suitable named patient use to a formal clinical trial. This new data in the two pediatric HSCT-TMA patients follows prior positive preclinical and ex-vivo studies in two other TMAs, Antiphospholipid syndrome and atypical hemolytic-uremic syndrome; Coversin is currently being investigated by Akari in a Phase II trial in patients with aHUS. Akari has three other clinical programs in development. Bullous pemphigoid is a severe blistering skin disease where the role of both C5 and LTB4 has recently been shown in an ex-vivo analysis of blister fluid from BP patients. Akari's Phase II trial in BP patients is currently recruiting, with initial data currently expected in the first quarter of 2019. Atopic keratoconjunctivitis is a sight-threatening surface of the eye condition, and is currently in Phase I/II, with initial data anticipated in the first quarter of 2019. Paroxysmal nocturnal haemoglobinuria, where Akari has an ongoing Phase III trial in naive patients as well as another active clinical trial in patients who are resistant to eculizumab. The PNH program is being advanced in a staged manner to ensure Akari has the opportunity to commit appropriate resources to the most promising of its clinical targets. Akari is continuing to evaluate partnering opportunities across its clinical programs.
|
